Posts Tagged ‘obesity’

Can we think global and act local on chronic diseases and obesity? At the United Nations General Assembly meeting this week, quite a few people gave it a try – with mixed results. At the end of the day yesterday, no one was terribly surprised when U.S. Health Secretary Robert F. Kennedy Jr. threw a […]

This one definitely sounded too good to be true from the start. A little bit of apple cider vinegar daily for young persons with obesity supposedly produced lower body weight, BMI, body fat ratio, blood sugar, triglycerides, and cholesterol. No side effects. However, this stunning piece of research on apple cider vinegar in obesity was […]

The Washington Examiner tells us we can prevent millions of cases of obesity and thousands of strokes simply by dropping twice-a-year time changes. “Study says.” Discover magazine says so, too. The Washington Post is a little more restrained. “We’d all be a little less prone to obesity and strokes if we ditched the switch.” Ditch […]

Yesterday Pfizer announced a $7.3 billion deal to buy Metsera, a company with an impressive obesity drugs portfolio. Roche, having spent $2.7 billion to acquire Carmot in 2023 and $1.6 billion in March on a deal with Zealand, yesterday confirmed its intent to spend everything it takes to become a market leader in obesity. “We […]

The emerging contest to dominate the market for oral tablets in obesity treatment became clear this week as news and PR dispatches flowed from EASD in Vienna. Aiming for a Mass Target With understated confidence, Lilly presented and published pivotal phase three data on orforglipron in NEJM. They did not run from the fact that […]

This week has been a flood of news from the EASD meeting in Vienna. Yesterday, the big news was an impressive win for kids 10-17 with type 2 diabetes in a study of tirzepatide. Researchers presented the SURPASS-PEDS trial and simultaneously published it in Lancet. At the end of the 30-week trial, tirzepatide in two […]

Today at EASD, investigators for the ATTAIN-1 pivotal phase three trial are presenting detailed results for orforglipron in obesity. These results, published yesterday in the New England Journal of Medicine, offer no big surprises. The effectiveness in this 72-week trial was acceptable. But a big question hangs in the air. Will orforglipron be the GLP-1 […]

Today in Nature Medicine, compelling new research tells that long-term outcomes with metabolic surgery are superior to the outcomes with GLP-1 agonists in persons with diabetes and obesity. These are impressive and important results. But we have to wonder if anyone is really listening. The enthusiasm for advanced obesity medicines is so great that many […]

A new study in Lancet suggests that we are overdue for fresh thinking about early childhood obesity prevention. This is because programs built upon a premise of engaging parents in the effort turn out to be ineffective. The conclusions of this research are stark: “This study is the most comprehensive individual participant data meta-analysis in […]

It’s almost funny. Except it’s not. This is deadly serious for people whose entire lives are shaped by obesity – people who need better access to care. The influential Institute for Clinical and Economic Review (ICER) issued a new draft report on the cost effectiveness of semaglutide and tirzepatide. In a nutshell, the report says […]